Quick Take
IGM Biosciences (IGMS) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement.
The firm is focused on the development of engineered IgM antibodies as cancer treatments.
IGMS is a very early stage firm seeking public capital to advance its novel treatment candidates.
When we learn management’s valuation assumptions, I’ll provide an update.
Company & Technology
Mountain View, California-based IGM was founded in 1993 as Palingen and currently develops engineered IgM antibodies for the treatment of cancer patients.
Management is headed